Eosinophilia: Clinical Trials

30 trials for Eosinophilia, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

17 completed, 6 unknown, 3 active not recruiting, 2 enrolling by invitation. 30 Phase 4.

By phase and status

PhaseTrialsStatus
Phase 430Completed 17, Unknown 6, Active not recruiting 3, Enrolling by invitation 2, Recruiting 1, Terminated 1

Follow Eosinophilia: new trials by email Literature Review of Eosinophilia trials Research Report on Eosinophilia

Trials (filtered) newest first · largest first

All 30 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
Fasenra: An Asthma Study
Budesonide-albuterol, Benralizumab - Eosinophilic Asthma, Severe Asthma
Phase 4Enrolling by invitationEndeavor Health402026-07-012026-09-15
Beyond EOsinophils: proteoMICS to Identify Potential Biomarker of Organ Damage and Response to MEPOLIZUMAB in EGPA
Mepolizumab 100 MG Injection [Nucala], Mepolizumab 300 mg - EGPA - Eosinophilic Granulomatosis With Polyangiitis, Severe Asthma
Phase 4Enrolling by invitationAzienda Ospedaliero Universitaria di Cagliari902025-10-172026-01-15
Effect of Dupilumab on the Muscle Function of the Esophagus (food Pipe) in Participants with Eosinophilic Esophagitis (EoE)
Dupilumab 300 MG/2 ML Subcutaneous Solution [DUPIXENT] - Eosinophilic Esophagitis (EoE)
Phase 4RecruitingUniversity of California, San Diego302024-11-102024-12-11
Dupilumab for Eosinophilic Esophagitis With Severe Strictures
Dupilumab - Eosinophilic Esophagitis, EoE
Phase 4Active not recruitingUniversity of North Carolina, Chapel Hill232024-05-162026-04-29
BenRalizumab Effect on Airway Remodeling in Severe asTHma
Benralizumab 30 mg/ml - Asthma; Eosinophilic, Airway Remodeling
Phase 4CompletedAristotle University Of Thessaloniki362024-03-012026-10-28
A Study Assessing Esophageal Function and Remodeling With Dupilumab Compared With Placebo for 24 Weeks Followed by 104 Weeks Open Label in Adult Participants With EoE (REMOdeling With Dupilumab in Eosinophilic Esophagitis Long-term Trial)
Dupilumab, Placebo - Eosinophilic Oesophagitis
Phase 4Active not recruitingSanofi692023-11-292026-09-30
A Real-world, Head-to-head Comparison of Dupilumab Versus Mepolizumab in Danish Patients With Chronic Rhinosinusitis With Nasal Polyps
dupilumab, mepolizumab - Chronic Rhinosinusitis With Nasal Polyps, Asthma; Eosinophilic
Phase 4Active not recruitingCopenhagen University Hospital, Rigshospitalet2202023-04-272025-07-01
BURAN: Benralizumab on Airway Dynamics in Severe Eosinophilic Asthma Using Functional Respiratory Imaging
Benralizumab - Asthma
Phase 4CompletedAstraZeneca452022-10-112025-03-25
Efficacy of Dupilumab on Facilitated Food Introduction in Eosinophilic Esophagitis
Eosinophilic Esophagitis (EoE) food introduction-1st, Eosinophilic Esophagitis (E0E) food introduction-2nd, Eosinophilic Esophagitis (EoE) Food introduction-3rd dose - Eosinophilic Esophagitis
Phase 4CompletedChildren's Hospital of Philadelphia212022-06-162025-11-10
Cycling of Topical Steroids for Treatment of EoE (Eosinopilic Esophagitis)
Fluticasone Propionate, Budesonide - Eosinophilic Esophagitis
Phase 4CompletedUniversity Hospitals Cleveland Medical Center232021-11-172024-11-07
Predictive Signature of Benralizumab Response
Benralizumab Prefilled Syringe - Asthma; Eosinophilic, Severe Asthma
Phase 4CompletedNantes University Hospital852021-10-112026-11-13
Efficacy and Safety Study of Mepolizumab 100 Milligram (mg) Subcutaneous (SC) in Indian Participants Aged Greater Than or Equal to (>=) 18 Years With Severe Eosinophilic Asthma
Mepolizumab, Salbutamol - Asthma
Phase 4CompletedGlaxoSmithKline1002021-06-292024-12-10
Efficacy of Reslizumab Dose Escalation in Patients With Severe Asthma
Reslizumab - Asthma; Eosinophilic
Phase 4CompletedMcMaster University102021-02-102024-01-25
Proton Pump Inhibitor (PPI) Response in Eosinophilic Esophagitis Assessed by Transnasal Endoscopy (TNE)
Omeprazole 20mg BID - Eosinophilic Esophagitis
Phase 4UnknownUniversity of Colorado, Denver902020-10-072024-07-03
A Study to Assess the Reduction of Daily Maintenance ICS/LABA Treatment Towards Anti-Inflammatory Reliever Treatment in Patients With Severe Eosinophilic Asthma Treated With Benralizumab
Symbicort®, Fasenra®, Ventolin® - Asthma, Severe Eosinophilic Asthma
Phase 4CompletedAstraZeneca1702020-07-272025-01-09
Anti-viral Effects of Azithromycin in Patients With Asthma and COPD
Azithromycin, Placebo oral tablet - Asthma, COPD
Phase 4UnknownBispebjerg Hospital1002020-03-022021-07-26
A Pragmatic Study to Investigate the Efficacy and Safety of Mepolizumab in Severe Uncontrolled Asthma in Brazil
Mepolizumab 100 MG [Nucala] - Eosinophilic Asthma
Phase 4UnknownUniversity of Sao Paulo General Hospital182020-01-092020-01-14
Benralizumab Airway Remodeling Study in Severe Eosinophilic Asthmatics
Benralizumab, Placebo - Asthma
Phase 4CompletedAstraZeneca752019-10-082026-11-13
Comparing Treatment Efficacy With Mepolizumab and Omalizumab in Severe Asthma - "Choosebetweenamab".
Mepolizumab, Omalizumab - Asthma, Eosinophilic Asthma
Phase 4UnknownUniversity of Newcastle, Australia2002018-11-032020-10-14
Inflammation Following Mepolizumab and Oral Corticosteroids in Asthma
Prednisolone, Placebo oral capsule - Asthma
Phase 4CompletedNHS Greater Glasgow and Clyde332018-10-192020-03-06

Showing 20 of 30. Sign in to see all of them.

Narrower conditions

Pulmonary Eosinophilia (18)  ·  Asthma (15)  ·  Eosinophilic Esophagitis (11)  ·  Lung Diseases (3)  ·  Esophagitis (2)  ·  Inflammation (2)  ·  Airway Remodeling (1)  ·  Bronchial Diseases (1)  ·  Chronic Disease (1)  ·  Churg-Strauss Syndrome (1)  ·  Constriction, Pathologic (1)  ·  Deglutition Disorders (1)  ·  Esophageal Diseases (1)  ·  Gastroenteritis (1)

Broader conditions

Hemic and Lymphatic Diseases (30)  ·  Hematologic Diseases (29)  ·  Leukocyte Disorders (29)  ·  Hypersensitivity (26)  ·  Hypersensitivity, Immediate (26)  ·  Immune System Diseases (25)  ·  Hypereosinophilic Syndrome (18)  ·  Respiratory Tract Diseases (17)  ·  Lung Diseases (15)  ·  Respiratory Hypersensitivity (15)  ·  Bronchial Diseases (14)  ·  Lung Diseases, Obstructive (14)  ·  Digestive System Diseases (11)  ·  Esophageal Diseases (10)

Interventions

benralizumab (6)  ·  mepolizumab (6)  ·  dupilumab (5)  ·  Fluticasone (4)  ·  Albuterol (3)  ·  Budesonide (3)  ·  BID protein, human (2)  ·  Omalizumab (2)  ·  Omeprazole (2)  ·  Prednisolone (2)  ·  Azithromycin (1)  ·  Biological Products (1)  ·  Budesonide, Formoterol Fumarate Drug Combination (1)  ·  Coal Tar (1)  ·  Cromolyn Sodium (1)

Sponsors

AstraZeneca (3)  ·  GlaxoSmithKline (2)  ·  University of North Carolina, Chapel Hill (2)  ·  Aristotle University Of Thessaloniki (1)  ·  Azienda Ospedaliero Universitaria di Cagliari (1)  ·  Azienda Policlinico Umberto I (1)  ·  Bispebjerg Hospital (1)  ·  Children's Hospital of Philadelphia (1)  ·  Claire Daniels (1)  ·  Copenhagen University Hospital, Rigshospitalet (1)  ·  Dallas VA Medical Center (1)  ·  Endeavor Health (1)  ·  Hamamatsu University (1)  ·  McMaster University (1)  ·  NHS Greater Glasgow and Clyde (1)

Countries

United States (15)  ·  United Kingdom (5)  ·  Canada (4)  ·  France (4)  ·  Denmark (3)  ·  Germany (3)  ·  Italy (3)  ·  Australia (2)  ·  Belgium (2)  ·  Brazil (2)  ·  Spain (2)  ·  Sweden (2)  ·  Argentina (1)  ·  Greece (1)  ·  India (1)

Top investigators

Evan S Dellon, MD, MPH (2)  ·  Celeste Porsbjerg, MD, PhD (1)  ·  Christian Pedersen, MD (1)  ·  Christian von Buchwald (1)  ·  Dr. David Jackson (1)  ·  Giselle Mosnaim, MD, MS (1)  ·  Ian Pavord (1)  ·  Jay A Lieberman, MD (1)  ·  Jonathan Spergel, MD, PhD (1)  ·  Kalliopi Domvri, Dr (1)  ·  Kingo Chida, MD, PhD (1)  ·  Marek Lommatzsch, MD (1)  ·  Mario Castro, MD (1)

Results publications

PMID 10049409, PMID 12045120, PMID 16329022, PMID 17919504, PMID 20920599, PMID 21037369, PMID 23567357, PMID 25614171, PMID 25858909, PMID 26142551, PMID 26247167, PMID 26426817, PMID 26513622, PMID 26685124, PMID 28461289, PMID 29221581, PMID 29544738, PMID 30009819, PMID 30708107, PMID 30872104, PMID 31499249, PMID 31657082, PMID 31798645, PMID 32762056, PMID 33009060, PMID 33369570, PMID 33971856, PMID 37131265, PMID 37343842, PMID 38071986, PMID 41038415, PMID 41084592, PMID 42458446, PMID 42861971

NIH funding

2015 (1), 2018 (1), 2019 (1), R01DK101856 (1)